Targeting the sphingolipid system as a therapeutic direction for glioblastoma

Melinda N. Tea, Santosh I. Poonnoose, Stuart M. Pitson

Research output: Contribution to journalReview articlepeer-review

21 Citations (Scopus)
6 Downloads (Pure)


Glioblastoma (GBM) is the most commonly diagnosed malignant brain tumor in adults. The prognosis for patients with GBM remains poor and largely unchanged over the last 30 years, due to the limitations of existing therapies. Thus, new therapeutic approaches are desperately required. Sphingolipids are highly enriched in the brain, forming the structural components of cell membranes, and are major lipid constituents of the myelin sheaths of nerve axons, as well as playing critical roles in cell signaling. Indeed, a number of sphingolipids elicit a variety of cellular responses involved in the development and progression of GBM. Here, we discuss the role of sphingolipids in the pathobiology of GBM, and how targeting sphingolipid metabolism has emerged as a promising approach for the treatment of GBM.

Original languageEnglish
Article number111
Number of pages25
Issue number1
Publication statusPublished - 1 Jan 2020
Externally publishedYes


  • Ceramide
  • Glioblastoma
  • Sphingolipid
  • Sphingosine 1-phosphate


Dive into the research topics of 'Targeting the sphingolipid system as a therapeutic direction for glioblastoma'. Together they form a unique fingerprint.

Cite this